Keros Therapeutics shares are trading lower after the company announced data from its ongoing Phase 2 clinical trial of KER-050 and preclinical data evaluating ALK2 inhibition at the 28th Annual Congress of the European Hematology Association.
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics shares are trading lower following the announcement of data from its ongoing Phase 2 clinical trial of KER-050 and preclinical data evaluating ALK2 inhibition at the 28th Annual Congress of the European Hematology Association.
June 09, 2023 | 5:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Keros Therapeutics shares are trading lower after announcing data from its ongoing Phase 2 clinical trial of KER-050 and preclinical data evaluating ALK2 inhibition.
The announcement of data from the ongoing Phase 2 clinical trial of KER-050 and preclinical data evaluating ALK2 inhibition has led to a decline in Keros Therapeutics' share price. This indicates that the market may have had higher expectations for the trial results, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100